Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Frazor Titus Edmondson III, Chief Legal Officer at Zai Lab (NASDAQ:ZLAB), sold 5,877 American Depositary Shares (ADSs) of the company on June 26, 2025, at a price of $36.132, for a total value of $212,347. The sale comes amid the stock’s impressive 106% return over the past year, with InvestingPro data showing particularly strong momentum in recent months, including a 36% gain over the last six months.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction decreased Edmondson’s direct ownership in the company to 39,098 ADSs. Based on current market prices, Zai Lab appears slightly undervalued according to InvestingPro’s Fair Value model, with analysts setting price targets ranging from $38.20 to $73.00.
On June 25, Edmondson also acquired 14,600 ADSs upon the vesting of Restricted Share Units (RSUs). The company maintains strong financial health with a current ratio of 3.26, holding more cash than debt on its balance sheet.
In other recent news, Zai Lab has garnered attention following Cantor Fitzgerald’s reaffirmation of an Overweight rating on the company’s stock. The analysts highlighted the promising potential of Zai Lab’s ZL-1310 treatment for extensive stage small cell lung cancer, with data showing a higher objective response rate compared to competitors. This development could lead to significant revenue generation, with potential sales estimated between $1-2 billion. Additionally, Cantor Fitzgerald expressed confidence in Zai Lab’s ability to navigate geopolitical challenges, noting that the company is unlikely to face delisting risks from U.S. exchanges due to its robust corporate structure. The firm also pointed out that Zai Lab’s operations in China remain largely unaffected by ongoing U.S.-China trade tensions, which might even provide licensing advantages. Moreover, Zai Lab’s Bemarituzumab is being closely watched as a potential growth driver, with Phase 3 trials for gastric cancer treatments underway. The analysts project that Bemarituzumab could significantly contribute to Zai Lab’s growth starting in 2027. Despite market pressures, Cantor Fitzgerald maintains a positive long-term outlook for Zai Lab, anticipating profitability by the fourth quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.